Antioxidants and mucolytics in COPD management: When (if ever) and in whom?

Current Drug Targets

Volumn 14, Issue 2, 2013, Pages 225-234

  Hillas, Georgios ^a   Nikolakopoulou, Sofia ^a   Hussain, Sabah ^b   Vassilakopoulos, Theodoros ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Antioxidants; COPD; N acetylcysteine; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CARBOCISTEINE; CIGARETTE SMOKE; ERDOSTEINE; FUDOSTEINE; GLUTATHIONE PEROXIDASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MUCOLYTIC AGENT; PLACEBO; PREDNISONE; REACTIVE OXYGEN METABOLITE; SALBUTAMOL; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NRF2;

ABSENCE OF SIDE EFFECTS; BREATHING MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIAPHRAGM; ELECTRON TRANSPORT; HUMAN; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; OXIDATIVE STRESS; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; SPIROMETRY;

ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; EMPHYSEMA; EXPECTORANTS; HUMANS; INFLAMMATION; MICE; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84873184252     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314020007     Document Type: Review

References (132)

1. Rahman I, Kinnula VL. Strategies to decrease ongoing oxidant burden in chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol 2012; 5: 293-309.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2011. Available at: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosismanagement. html (accessed on 15 March 2012).
3. Church T, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 1985; 64: 111-26.
4. Rahman I, MacNee W. Role of oxidants/antioxidants in smokinginduced airways diseases. Free Rad Biol Med 1996; 21: 669-81.
5. MacNee W. Oxidants/Antioxidants and COPD. CHEST 2000; 117: 303-17.
6. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 258-66.
7. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2: 50-60.
8. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Clin Chest Med 2007; 28: 479-513.
9. MacNee W, Rahman I. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med 2001; 7: 55-62.
10. Rahman I, Adcock IM: Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28: 219-42.
11. Sanguinetti CM: Oxidant/antioxidant imbalance: role in the pathogenesis of COPD. Respiration 1992; 59: 20-3.
12. Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis 2011; 6: 413-21.
13. Andrade Jr DR, Souza RB, Santos SA, Andrade DR. Oxygen free radicals and pulmonary disease. J Bras Pneumol 2005; 31: 60-8.
14. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
15. Mak JC. Pathogenesis of COPD. Part II. Oxidative-antioxidative imbalance. Int J Tuberc Lung Dis 2008; 12: 368-74.
16. Rajendrasozhan S, Yang SR, Edirisinghe I, et al. Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid Redox Signal 2008; 10: 799-811.
17. Rahman I, MacNee W. Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol 2012; 12: 256-65
18. Janssen-Heininger YM, Persinger RL, Korn SH, et al. Reactive nitrogen species and cell signaling: implications for death or survival of lung epithelium. Am J Respir Crit Care Med 2002; 166: 9-16
19. Rahman I, MacNee W. Role of transcription factors in inflammatory lung diseases. Thorax 1998; 53: 601-12.
20. Rahman I. Reproducibility of oxidative stress biomarkers in breath condensate: are they reliable? Eur Respir J 2004; 23: 183-4.
21. Rahman I: Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis. 2008; 2: 351-74.
22. Sofic E, Rimpapa Z, Kundurovic Z, et al. Antioxidant capacity of the neurohormone melatonin. J Neural Transm 2005; 112: 349-58.
23. de Matos Cavalcante AG, de Bruin PF, de Bruin VM, et al. Melatonin reduces lung oxidative stress in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebocontrolled study. J Pineal Res. 2012 Mar 19. [Epub ahead of print].
24. Lannan S, Donaldson K, Brown D, et al. Effects of cigarette smoke and its condensates on alveolar cell injury in vitro. Am J Physiol 1994; 266:92-100.
25. Rahman I, Li XY, Donaldson K, et al. Cigarette smoke glutathione metabolism and epithelial permeability in rat lungs. Biochem Soc Trans 1995; 23: 235.
26. Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 349-55.
27. Fiorini G, Crespi S, Rinaldi M, et al. Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction. Biomed Pharmacother 2000; 54: 274-8.
28. Morrison D, Rahman I, Lannan S, MacNee W. Epithelial permeability, inflammation and oxidant stress in the airspaces of smokers. Am J Respir Crit Care Med 1999; 159: 473-79.
29. van der Toorn M, Smit-de Vries MP, Slebos DJ, et al. Cigarette smoke irreversibly modifies glutathione in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2007; 293: 1156-62.
30. Javesghani D, Magder SA, Barreiro E, et al. Molecular characterization of a superoxide-generating NAD(P)H oxidase in the ventilator muscles. Am J Respir Crit Care Med 2002; 165: 412-8.
31. Park HS, Kim SR, Lee YC. Impact of oxidative stress on lung diseases. Respirology 2009; 14: 27-38.
32. Horváth I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005; 26: 523-48.
33. Hillas G, Loukides S, Kostikas K, Bakakos P. Biomarkers obtained by non-invasive methods in patients with COPD: where do we stand, what do we expect? Curr Med Chem. 2009; 16: 2824-38.
34. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1693-722
35. Montuschi P, Barnes PJ. Analysis of exhaled breath condensate for monitoring airway inflammation. Trends Pharmacol Sci 2002; 23: 232-7.
36. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162: 1175-7.
37. Reid MB. Redox modulation of skeletal muscle contraction: what we know and what we don't. J Appl Physiol 2001; 90: 724-31.
38. Vassilakopoulos T, Hussain SN. Ventilatory muscle activation and inflammation: cytokines, reactive oxygen species, and nitric oxide. J Appl Physiol 2007; 102: 1687-95.
39. Borzone G, Zhao B, Merola AJ, et al. Detection of free radicals by electron spin resonance in rat diaphragm after resistive loading. J Appl Physiol 1994; 77: 812-8.
40. Anzueto A, Andrade FH, Maxwell LC, et al. Resistive breathing activates the glutathione redox cycle and impairs performance of rat diaphragm. J Appl Physiol 1992; 72: 529-34.
41. Hussain SN, Matar G, Barreiro E, et al. Modifications of proteins by 4-hydroxy-2-nonenal in the ventilatory muscles of rats. Am J Physiol Lung Cell Mol Physiol 2006; 290: 996-1003.
42. Supinski G, Nethery D, Stofan D, et al. Oxypurinol administration fails to prevent free radical-mediated lipid peroxidation during loaded breathing. J Appl Physiol 1999; 87: 1123-31.
43. Supinski GS, Stofan D, Ciufo R, et al. N-acetylcysteine administration alters the response to inspiratory loading in oxygensupplemented rats. J Appl Physiol 1997; 82: 1119-25.
44. Sigala I, Zacharatos P, Toumpanakis D, et al. MAPKs and NF-kB differentially regulate cytokine expression in the diaphragm in response to resistive breathing:t he role of oxidative stress. Am J Physiol Regul Integr Comp Physiol. 2011; 300: 1152-62.
45. Nethery D, Stofan D, Callahan L, et al. Formation of reactive oxygen species by the contracting diaphragm is PLA2 dependent. J Appl Physiol 1999; 87: 792-800.
46. Nethery D, Callahan LA, Stofan D, et al. PLA2 dependence of diaphragm mitochondrial formation of reactive oxygen species. J Appl Physiol 2000; 89: 72-80.
47. Javesghani D, Magder SA, Barreiro E, et al. Molecular characterization of a superoxide-generating NAD(P)H oxidasein the ventilatory muscles. Am J Respir Crit Care Med 2002; 165: 412-8.
48. Marin-Corral J, Minguella J, Ramírez-Sarmiento AL, et al. Oxidised proteins and superoxide anion production in the diaphragm of severe COPD patients. Eur Respir J 2009; 33: 1309-19.
49. Barreiro E, de la Puente B, Minguella J, et al. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 171: 1116-24.
50. Barreiro E, Peinado VI, Galdiz JB, et al. ENIGMA in COPD Project. Cigarette smoke-induced oxidative stress: A role in chronic obstructive pulmonary disease skeletal muscle dysfunction. Am J Respir Crit Care Med. 2010; 182: 477-88.
51. Vassilakopoulos T, Zakynthinos S, Roussos C. Strenuous resistive breathing induces proinflammatory cytokines and stimulates the HPA axis in humans. Am J Physiol 1999; 277: 1013-19.
52. Vassilakopoulos T, Katsaounou P, Karatza MH, et al. Strenuous resistive breathing induces plasma cytokines: role of antioxidants and monocytes. Am J Respir Crit Care Med. 2002; 166: 1572-8.
53. Rahman I. Oxidative stress and gene transcription in asthma and chronic obstructive pulmonary disease: antioxidant therapeutic targets. Curr Drug Targets Inflamm Allergy. 2002; 1: 291-315.
54. Pelletier O. Vitamin C status of cigarette smokers and nonsmokers. Am J Clin Nutr 1970; 23: 520-4.
55. Chow CK, Thacker RR, Changchit C, et al. Lower levels of vitamin C and carotenes in plasma of cigarette smokers. J Am Coll Nutr 1986; 5: 305-12.
56. Duthie GG, Arthur JR, James WP. Effects of smoking and vitamin E on blood antioxidant status. Am J Clin Nutr 1991; 53: 1061-3.
57. van Antwerpen L, Theron AJ, Myer MS, et al Cigarette smokemediated oxidant stress, phagocytes, vitamin C, vitamin E, and tissue injury. Ann N Y Acad Sci 1993; 686: 53-65.
58. Mezzetti A, Lapenna D, Pierdomenico SD, et al. Vitamins E, C and lipid peroxidation in plasma and arterial tissue of smokers and nonsmokers. Atherosclerosis 1995; 112: 91-9.
59. Bridges AB, Scott NA, Parry GJ, Belch JJ. Age, sex, cigarette smoking and indices of free radical activity in healthy humans. Eur J Med 1993; 2: 205-8.
60. Tug T, Karatas F, Terzi SM. Antioxidant vitamins (A, C and E) and malondialdehyde levels in acute exacerbation and stable periods of patients with chronic obstructive pulmonary disease. Clin Invest Med 2004; 27: 123-8.
61. Agacdiken A, Basyigit I, Ozden M, et al. The effects of antioxidants on exercise-induced lipid peroxidation in patients with COPD. Respirology 2004; 9: 38-42.
62. Schünemann HJ, Freudenheim JL, Grant B. Epidemiologic evidence linking antioxidant vitamins to pulmonary function and airway obstruction. Epidemiol Rev 2001; 23: 248-67.
63. Smit HA. Chronic obstructive pulmonary disease, asthma and protective effects of food intake: from hypothesis to evidence? Respir Res 2001; 2: 261-4.
64. Smit HA, Grievink L, Tabak C: Dietary influences on chronic obstructive lung disease and asthma: a review of the epidemiological evidence. Proc Nutr Soc 1999; 58: 309-19.
65. Schünemann HJ, Grant BJ, Freudenheim JL, et al. The relation of serum levels of antioxidant vitamins C and E, retinol and carotenoids with pulmonary function in the general population. Am J Respir Crit Care Med 2001; 163: 1246-55.
66. Kelly FJ. Vitamins and respiratory disease: antioxidant micronutrients in pulmonary health and disease. Proc Nutr Soc 2005; 64: 510-26.
67. Hu G, Cassano PA. Antioxidant nutrients and pulmonary function: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Epidemiol 2000; 151: 975-81.
68. McKeever TM, Lewis SA, Smit HA, et al. A multivariate analysis of serum nutrient levels and lung function. Respir Res 2008; 9: 67.
69. Grievink L, Smit HA, Ocké MC, van 't Veer P, Kromhout D. Dietary intake of antioxidant (pro)-vitamins, respiratory symptoms and pulmonary function: the MORGEN study. Thorax 1998; 53: 166-71.
70. Tabak C, Smit HA, Heederik D, Ocké MC, Kromhout D. Diet and chronic obstructive pulmonary disease: independent beneficial effects of fruits, whole grains, and alcohol (the MORGEN study). Clin Exp Allergy 2001; 31: 747-55.
71. Keranis E, Makris D, Rodopoulou P, et al. Impact of dietary shift to higher antioxidant foods in COPD: A Randomized Trial. Eur Respir J 2010; 36: 774-80.
72. Daga MK, Chhabra R, Sharma B, et al. Effects of exogenous vitamin E supplementation on the levels of oxidants and antioxidants in chronic obstructive pulmonary disease. J Biosci 2003; 28: 7-11.
73. Nadeem A, Raj HG, Chhabra SK. Effect of vitamin E supplementation with standard treatment on oxidant-antioxidant status in chronic obstructive pulmonary disease. Indian J Med Res 2008; 128: 705-11.
74. Wu TC, Huang YC, Hsu SY, et al. Vitamin E and vitamin C supplementation in patients with chronic obstructive pulmonary disease. Int J Vitam Nutr Res 2007; 77: 272-9.
75. Schwartz J, Weiss ST. Dietary factors and their relation to respiratory symptoms. The Second National Health and Nutrition Examination Survey. Am J Epidemiol 1990; 132: 67-76.
76. Zasloff M. Fighting infections with vitamin D. Nat Med 2006; 12: 388-90.
77. Tug T, Karatas F, Terzi SM. Antioxidant vitamins (A, C and E) and malondialdehyde levels in acute exacerbation and stable periods of patients with chronic obstructive pulmonary disease. Clin Invest Med 2004; 27: 123-8.
78. Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009; 169: 384-90.
79. Chishimba L, Thickett DR, Stockley RA, Wood AM. The vitamin D axis in the lung: a key role for vitamin D-binding protein. Thorax 2010; 65: 456-62.
80. Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. Chest 2005; 128: 3792-8.
81. Gombart AF. The vitamin D-antimicrobial peptide pathway and its role in protection against infection. Future Microbiol 2009; 9: 1151-65.
82. Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 2008; 4: 80-90.
83. Kung T, Springer J, Doehner W, Anker SD, von Haehling S. Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference. Expert Opin Investig Drugs 2010; 19: 579-85.
84. Cotgreave IA. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol 1997; 38: 205-27.
85. Bridgeman MM, Marsden M, Selby C, Morrison D, MacNee W. Effect of N-acetylcysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 1994; 49: 670-75.
86. Kasielski M, Nowak D. Long-term administration of Nacetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 2001; 95: 448-56
87. De Benedetto F, Aceto A, Dragani B, et al. Long-term oral nacetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther 2005; 18: 41-7.
88. Van Schooten FJ, Besaratinia A, De Flora S, et al. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol Biomarkers Prev 2002; 11: 167-75.
89. Lukas R, Schärling B, Schultze-Werninghaus G, Gillissen A. Antioxidant treatment with N-acetylcysteine and vitamin C in patients with chronic bronchitis. Dtsch Med Wochenschr 2005; 130: 563-7.
90. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16: 253-62.
91. Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; 2: CD001287
92. Sutherland ER, Crapo JD, Bowler RP. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD. 2006; 3: 195-202.
93. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. Nacetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 795-98.
94. Mata M, Morcillo E, Gimeno C, Cortijo J. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol. 2011; 82: 48-55.
95. Geiler J, Michaelis M, Naczk P, et al. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol. 2010; 79: 413-20.
96. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552-60.
97. Black PN, Morgan-Day A, McMillan TE, Poole PJ, Young RP. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med 2004; 4: 13
98. Braga PC, Borsa M, De Angelis L, et al. Pharmacokinetic behavior of S-carboxymethylcysteine-Lys in patients with chronic bronchitis. Clin Ther 1982; 4: 480-8.
99. Braga PC, Allegra L, Rampoldi C, Ornaghi A, Beghi G. Longlasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine-lysine to patients with chronic bronchitis. Respiration 1990; 57: 353-58.
100. Edwards GF, Steel AE, Scott JK, Jordan JW. Scarboxymethylcysteine in the fluidification of sputum and treatment of chronic airway obstruction. Chest 1976; 70: 506-13.
101. Carpagnano GE, Resta O, Foschino-Barbaro MP, et al. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMCLys). Eur J Pharmacol 2004; 505: 169-175.
102. Hanaoka M, Droma Y, Chen Y, et al. Carbocisteine protects against emphysema induced by cigarette smoke extract in rats. Chest 2011; 139: 1101-8.
103. Sumitomo T, Nakata M, Yamaguchi M, Terao Y, Kawabata S. S carboxymethylcysteine inhibits adherence of Streptococcus pneumoniae to human alveolar epithelial cells. J Med Microbiol 2012; 61: 101-8.
104. Cakan G, Turkoz M, Turan T, Ahmed K, Nagatake T. Scarboxymethylcysteine inhibits the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells. Microb Pathog 2003; 34: 261-5.
105. Zheng CH, Ahmed K, Rikitomi N, Martinez G, Nagatake T. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol 1999; 43: 107-13.
106. Tatsumi K, Fukuchi Y. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc 2007; 55: 1884-6.
107. Yamaya M, Nishimura H, Shinya K, et al. Inhibitory effects of carbocisteine on type A seasonal influenza virus infection in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2010; 299: 160-8.
108. Allegra L, Cordaro CI, Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. Respiration 1996; 63: 174-80.
109. Yasuda H, Yamaya M, Sasaki T, et al. Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc 2006; 54: 378-80.
110. Zheng JP, Kang J, Huang SG, et al. Effect of carbocysteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008; 371: 2013-8.
111. Moretti M, Marchioni CF. An overview of erdosteine antioxidant activity in experimental research. Pharmacol Res. 2007; 55: 249-54.
112. Dal Negro RW. Erdosteine: antitussive and anti-inflammatory effects. Lung 2008; 186: 70-73.
113. Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Expert Rev Respir Med 2007; 1: 307-16.
114. Dal Negro RW, Visconti M, Tognella S, Micheletto C. Erdosteine affects eicosanoid production in COPD. Int J Clin Pharmacol Ther 2011; 49: 41-5.
115. Moretti M, Bottrighi P, Dallari R, et al.: The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res 2004; 30: 143-52.
116. Moretti M. Erdosteine: its relevance in COPD treatment. Expert Opin Drug Metab Toxicol 2009; 5: 333-43
117. Cazzola M, Floriani I, Page CP. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a metaanalysis of individual patient data. Pulm Pharmacol Ther 2010; 23: 135-44.
118. Rhee CK, Kang CM, You MB, et al. Effect of fudosteine on mucin production. Eur Respir J 2008; 32: 1195-202.
119. Osoata GO, Hanazawa T, Brindicci C, et al. Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine. Chest 2009; 135: 1513-20.
120. Komatsu H, Yamaguchi S, Komorita N, et al. Inhibition of endotoxin-and antigen-induced airway inflammation by fudosteine, a mucoactive agent. Pulm Pharmacol Ther 2005; 18: 121-7.
121. Kinnula VL, Crapo JD. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med. 2003; 167: 1600-19.
122. Tse HM, Milton MJ, Piganelli JD. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigenpresenting cells: implication for their use in targeting oxidationreduction reactions in innate immunity. Free Radic Biol Med 2004; 36: 233-47.
123. Chang LY, Crapo JD. Inhibition of airway inflammation and hyperreactivity by an antioxidant mimetic. Free Radic Biol Med 2002; 33: 379-86.
124. Tuder RM, Zhen L, Cho CY, et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol 2003; 29: 88-97
125. Rosenthal RA, Huffman KD, Fisette LW, et al. Orally available Mn porphyrins with superoxide dismutase and catalase activities. J Biol Inorg Chem 2009; 14: 979-91.
126. Sharpe MA, Ollosson R, Stewart VC, Clark JB. Oxidation of nitric oxide by oxomanganese-saln complexes: a new mechanism for cellular protection by superoxide dismutase/catalase mimetics. Biochem J 2002; 366: 97-107.
127. Smith KR, Uyeminami DL, Kodavanti UP, et al. Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. Free Radic Biol Med 2002; 33: 1106-14.
128. Tollefson AK, Oberley-Deegan RE, Butterfield KT, et al. Endogenous enzymes (NOX and ECSOD) regulate smoke-induced oxidative stress. Free Radic Biol Med 2010; 49: 1937-46.
129. Yao H, Arunachalam G, Hwang JW, et al. Extracellular superoxide dismutase protects against pulmonary emphysema by attenuating oxidative fragmentation of ECM. Proc Natl Acad Sci USA 2010; 107: 15571-6.
130. Jozsef L, Filep JG. Selenium-containing compounds attenuate peroxynitrite-mediated NF-kappaB and AP-1 activation and interleukin-8 gene and protein expression in human leukocytes. Free Radic Biol Med 2003; 35: 1018-27.
131. Haddad el B, McCluskie K, Birrell MA, et al. Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation. J Immunol 2002; 169: 974-82.
132. Duong C, Seow HJ, Bozinovski S, et al. Glutathione peroxidase-1 protects against cigarette smoke-induced lung inflammation in mice. Am J Physiol Lung Cell Mol Physiol 2010; 299: 425-33.